2022 ASCO Annual Meeting*

Download All
June 3-7, 2022; Chicago, Illinois
Expert faculty review and share their insights and perspectives on key findings in hematologic malignancies presented at the 2022 ASCO Annual Meeting.
John M. Burke, MD
Shaji K. Kumar, MD
Eunice S. Wang, MD

Hematologic Malignancies

Slidesets ASCEMBL: 96-Wk Update of Asciminib vs Bosutinib for CML-CP Previously Treated With ≥2 TKIs
Slidesets Phase III IDHENTIFY Trial of Enasidenib vs Conventional Care in Late-Stage IDH2-Mutated R/R AML: Analysis by IDH2 Mutation
Slidesets Pre-MEASURE: Retrospective Analysis of the Prognostic Significance of NGS-MRD Testing in Patients With AML in First Remission Prior to Allogeneic HCT
Slidesets Phase II Trial of Crenolanib and 7+3 Chemotherapy in Newly Diagnosed FLT3-Mutated AML: Long-term Results
Slidesets Phase II Trial of Ponatinib + Blinatumomab in Adults With Ph+ ALL
Slidesets Mini-HyperCVD + Inotuzumab Ozogamicin ± Blinatumomab in Older Adults With Newly Diagnosed Ph-Negative B-Cell ALL: Updated Phase II Results
Slidesets Phase Ib Trial of Frontline Anti-CD47 Antibody Magrolimab + Azacitidine in TP53-Mutated AML
Slidesets Pivotal Phase II Trial of Glofitamab in R/R DLBCL
Slidesets ECHELON-1: OS Analysis of First-line Brentuximab Vedotin + AVD vs ABVD in Advanced Classical Hodgkin Lymphoma
Slidesets ROSEWOOD Primary Analysis: Phase II Trial of Zanubrutinib and Obinutuzumab vs Obinutuzumab Alone in R/R Follicular Lymphoma
Slidesets Phase I/II Study of Pembrolizumab + Favezelimab, an Anti–LAG-3 mAb, in R/R Classical Hodgkin Lymphoma
Slidesets CAPTIVATE: 3-Yr Follow-up Analysis From the Fixed-Duration Cohort of First-line Ibrutinib + Venetoclax for CLL/SLL
Slidesets Phase I/II Trial of Zilovertamab, an Anti-ROR1 Antibody, Plus Ibrutinib in MCL or CLL
Slidesets Epcoritamab, a CD3 x CD20 Bispecific Antibody, Plus R-CHOP in Untreated High-Risk DLBCL: Updated Analysis of Phase I/II EPCORE NHL-2 Trial
Slidesets Epcoritamab, a CD3 x CD20 Bispecific Antibody, Plus R2 in R/R Follicular Lymphoma: Updated Analysis of Phase I/II EPCORE NHL-2 Trial
Slidesets ASCEND: 4-Yr Follow-up Analysis of Acalabrutinib vs Rituximab + Idelalisib or Bendamustine in Relapsed/Refractory CLL
Slidesets ELEVATE-TN: 5-Yr Update of Acalabrutinib ± Obinutuzumab vs Obinutuzumab + Chlorambucil in Treatment-Naive CLL
Slidesets Phase III ATLAS Trial of Carfilzomib, Lenalidomide, and Dexamethasone vs Lenalidomide Alone as Maintenance After ASCT in Patients With NDMM
Slidesets First-in-Human Study of GC012F: BCMA/CD19 Dual-Targeted CAR T-Cell Therapy for Relapsed/Refractory Myeloma
Slidesets MajesTEC-1: Update From Phase I/II Trial of the BCMA x CD3 Bispecific Antibody Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma
Slidesets DETERMINATION: Phase III Trial of VRd ± ASCT With Ongoing Lenalidomide Maintenance in Patients With NDMM
Slidesets SHINE: First-line Ibrutinib + Bendamustine/Rituximab Followed by Rituximab Maintenance in Older Patients With MCL

Expert faculty review and share their insights and perspectives on key studies on the management of leukemias, lymphomas, and multiple myeloma presented at the 2022 American Society of Clinical Oncology Annual Meeting.

John M. Burke, MD Shaji K. Kumar, MD Eunice S. Wang, MD Physicians: maximum of 1.5 AMA PRA Category 1 Credits™ Released: September 13, 2022 Expired: No longer available for credit
Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AbbVie
AstraZeneca
Gilead Sciences, Inc.
Merck Sharp & Dohme Corp.
Novartis Pharmaceuticals Corporation
Seagen

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings